Caron A Jacobson

Caron A Jacobson

UNVERIFIED PROFILE

Are you Caron A Jacobson?   Register this Author

Register author
Caron A Jacobson

Caron A Jacobson

Publications by authors named "Caron A Jacobson"

Are you Caron A Jacobson?   Register this Author

38Publications

895Reads

25Profile Views

Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.

Expert Opin Biol Ther 2019 Nov 25;19(11):1157-1164. Epub 2019 Jul 25.

Department of Medical Oncology, Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1644316DOI Listing
November 2019

Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist.

Oncologist 2019 Oct 4. Epub 2019 Oct 4.

Washington University School of Medicine and Siteman Cancer Center, St. Louis, Missouri, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0395DOI Listing
October 2019

Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.

Hematol Oncol Clin North Am 2019 Aug 10;33(4):687-705. Epub 2019 May 10.

Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2019.03.005DOI Listing
August 2019

Redefining Non-Hodgkin Lymphoma: Using Genomic Subtypes to Improve Treatment Options.

Authors:
Caron A Jacobson

Hematol Oncol Clin North Am 2019 Aug 15;33(4):xiii-xiv. Epub 2019 May 15.

Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2019.04.005DOI Listing
August 2019

Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Expert Rev Hematol 2019 Mar 18;12(3):195-205. Epub 2019 Mar 18.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
March 2019

CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma.

Authors:
Caron A Jacobson

J Clin Oncol 2019 Feb 13;37(4):328-335. Epub 2018 Dec 13.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01457
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01457DOI Listing
February 2019

CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions.

J Natl Cancer Inst 2019 Feb 11. Epub 2019 Feb 11.

Dana Farber Cancer Institute, Boston MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz017DOI Listing
February 2019

Immunotherapy in aggressive B-cell lymphomas.

Best Pract Res Clin Haematol 2018 09 23;31(3):299-305. Epub 2018 Jul 23.

Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216926183005
Publisher Site
http://dx.doi.org/10.1016/j.beha.2018.07.015DOI Listing
September 2018

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

N Engl J Med 2017 12 10;377(26):2531-2544. Epub 2017 Dec 10.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.S.N., J.R.W.); H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (F.L.L., J.C.C.); Washington University and Siteman Cancer Center, St. Louis (N.L.B., A. Ghobadi); University of Miami, Miami (L.J.L., K.V.K.); Stanford University, Stanford (D.B.M., R.L.), City of Hope National Medical Center, Duarte (T.S.), University of California at Los Angeles, Los Angeles (J.M.T.), University of California at San Diego, San Diego (J.E.C.), and Kite Pharma, Santa Monica (A.B., J.R., L.N., Y.J., J.A., M.E., D.C., J.W., W.Y.G.) - all in California; Dana-Farber Cancer Institute, Boston (C.A.J., E.D.J.); Montefiore Medical Center, Bronx (I.B.), and the University of Rochester School of Medicine, Rochester (J.W.F., P.R.) - both in New York; Vanderbilt University Medical Center (O.O.O.) and the Sarah Cannon Research Institute and Tennessee Oncology (I.W.F.), Nashville; Mayo Clinic, Rochester, MN (Y.L., T.E.W.); Loyola University Medical Center, Maywood, IL (P.J.S.); John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ (A. Goy); Cleveland Clinic, Cleveland (B.T.H., M.R.S.); Karmanos Cancer Center, Wayne State University, Detroit (A.D.); University of Iowa Carver College of Medicine, Iowa City (U.F.); Colorado Blood Cancer Institute, Denver (P.M.S.); Banner M.D. Anderson Cancer Center, Gilbert, AZ (J.M.); and Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (I.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1707447DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485PMC
December 2017

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

J Clin Oncol 2017 Jan 24;35(1):24-31. Epub 2016 Oct 24.

Alex F. Herrera, Matthew Mei, Lawrence Low, Joo Y. Song, Victoria Bedell, Lithua Budde, Wing C. Chan, Robert Chen, Joyce Murata-Collins, Auayporn P. Nademanee, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Amrita Krishnan, Tanya Paris, Tracey Stiller, Joycelynne M. Palmer, City of Hope National Medical Center, Duarte, CA; Haesook T. Kim, Jennifer R. Brown, Matthew S. Davids, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Ann S. LaCasce, David M. Weinstock, Scott J. Rodig, Philippe Armand, Dana-Farber Cancer Institute; Gabriel K. Griffin, Reid W. Merryman, Christine Pak, Heather Sun, Brigham and Women's Hospital; German A. Pihan, Beth Israel Deaconess Medical Center; and Aliyah R. Sohani, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455688PMC
January 2017

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 07 11;30(1):183. Epub 2016 Jul 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.06.008DOI Listing
July 2016

Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.

Curr Hematol Malig Rep 2016 06;11(3):218-23

Department of Hematologic Malignancies, Division of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-016-0321-6DOI Listing
June 2016

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Authors:
Elizabeth C Townsend Mark A Murakami Alexandra Christodoulou Amanda L Christie Johannes Köster Tiffany A DeSouza Elizabeth A Morgan Scott P Kallgren Huiyun Liu Shuo-Chieh Wu Olivia Plana Joan Montero Kristen E Stevenson Prakash Rao Raga Vadhi Michael Andreeff Philippe Armand Karen K Ballen Patrizia Barzaghi-Rinaudo Sarah Cahill Rachael A Clark Vesselina G Cooke Matthew S Davids Daniel J DeAngelo David M Dorfman Hilary Eaton Benjamin L Ebert Julia Etchin Brant Firestone David C Fisher Arnold S Freedman Ilene A Galinsky Hui Gao Jacqueline S Garcia Francine Garnache-Ottou Timothy A Graubert Alejandro Gutierrez Ensar Halilovic Marian H Harris Zachary T Herbert Steven M Horwitz Giorgio Inghirami Andrew M Intlekofer Moriko Ito Shai Izraeli Eric D Jacobsen Caron A Jacobson Sébastien Jeay Irmela Jeremias Michelle A Kelliher Raphael Koch Marina Konopleva Nadja Kopp Steven M Kornblau Andrew L Kung Thomas S Kupper Nicole R LeBoeuf Ann S LaCasce Emma Lees Loretta S Li A Thomas Look Masato Murakami Markus Muschen Donna Neuberg Samuel Y Ng Oreofe O Odejide Stuart H Orkin Rachel R Paquette Andrew E Place Justine E Roderick Jeremy A Ryan Stephen E Sallan Brent Shoji Lewis B Silverman Robert J Soiffer David P Steensma Kimberly Stegmaier Richard M Stone Jerome Tamburini Aaron R Thorner Paul van Hummelen Martha Wadleigh Marion Wiesmann Andrew P Weng Jens U Wuerthner David A Williams Bruce M Wollison Andrew A Lane Anthony Letai Monica M Bertagnolli Jerome Ritz Myles Brown Henry Long Jon C Aster Margaret A Shipp James D Griffin David M Weinstock

Cancer Cell 2016 04;29(4):574-586

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, 450 Brookline Avenue, Dana 510B, MA 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.03.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5177991PMC
April 2016

Rethinking Prognosis and Therapy for Follicular Lymphoma.

J Clin Oncol 2015 Aug 13;33(23):2489-91. Epub 2015 Jul 13.

Dana-Farber Cancer Institute; and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.3256DOI Listing
August 2015

Is observation dead in follicular lymphoma? Still appropriate.

J Natl Compr Canc Netw 2015 Mar;13(3):367-70

From Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2015.0047DOI Listing
March 2015

One size does not fit all in follicular lymphoma.

J Clin Oncol 2013 Sep 19;31(27):3307-8. Epub 2013 Aug 19.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.0454DOI Listing
September 2013

First-line treatment of indolent lymphoma: axing CHOP?

Lancet 2013 Apr 20;381(9873):1163-5. Epub 2013 Feb 20.

Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(12)61965-5DOI Listing
April 2013

Early stage follicular lymphoma, current management and controversies.

Curr Opin Oncol 2012 Sep;24(5):475-9

Department of Hematologic Malignancies, Division of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e328356898bDOI Listing
September 2012

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART.

Adv Hematol 2012 5;2012:507257. Epub 2012 Jan 5.

. Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/507257DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261478PMC
August 2012

Follicular lymphoma: to treat or not to treat is no longer the question.

J Natl Cancer Inst 2012 Jan 21;104(1):3-5. Epub 2011 Dec 21.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr498DOI Listing
January 2012

Time to put the CAR-T before the horse.

Blood 2011 Nov;118(18):4761-2

Dana-Farber Cancer Institute, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2011-09-376137DOI Listing
November 2011

Lymphoma: risk and response after solid organ transplant.

Oncology (Williston Park) 2010 Sep;24(10):936-44

Division of Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
September 2010

Unusual uterine recurrence of primary central nervous system lymphoma.

Clin Adv Hematol Oncol 2006 Sep;4(9):697-8, discussion 699-700

Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
September 2006